ref-id,title,url,parent_key
F1718,Peg-interferon FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/718/original/peg.pdf?1538425761,BE0002433
F1719,Peg-interferon alfa-2b FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/719/original/Peg_interferon_Alpha_2b.pdf?1538425985,BE0002433
F1814,Sylatron FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/814/original/103949s5153lbl.pdf?1539291183,BE0002793
F1722,PEG-Intron package insert,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/722/original/PEG-Intron_%28Peginterferon_alfa-2b%29_Package_Insert.pdf?1538428037,BE0002433
F1694,Fluvoxamine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/694/original/Fluvoxamine_FDA_label.pdf?1538148014,BE0002433
F3283,QSYMIA (phentermine/topiramate) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/283/original/fda.pdf?1549057509,BE0002638
F1635,"CYp1A3 CTEP document, cancer.gov",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/635/original/cyp1a2.doc?1537809665,BE0002433
F1636,Companion Dx reference lab document: EXPANDED TEST OFFERING IN PHARMACOGENOMICS: CYP1A2,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/636/original/PGX_CYP1A2_V11.15.pdf?1537809788,BE0002433
F1870,Sildenafil FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/870/original/Sildenafil_FDA_label.pdf?1539705689,BE0002793
F1612,List of drugs that may have potential CYP2E1 interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/612/original/cyp2e1.doc?1537551487,BE0003533
F3202,Protonix delayed release and oral suspension FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/202/original/Protonix_Delayed_relase_and_ora_susp.pdf?1548780962,BE0002638
F1709,Citalopram FDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/709/original/fda_lalbel_citalopram.pdf?1538411342,BE0002433
F3289,"MedSafe NZ Data Sheet, Citalopram",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/289/original/ArrowCitalopramtab.pdf?1549058792,BE0002433
F4661,FDA Label - Lovastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/661/original/FDA_Label_-_Lovastatin.pdf?1564095428,BE0002638
F4664,Health Canada Monograph - Lovastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/664/original/Health_Canada_Monograph_-_Lovastatin.PDF?1564095447,BE0002638
F3010,Mesalazine FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/010/original/091640Orig1s000lbl.pdf?1548099366,BE0003608
F1805,Get to Know an Enzyme: CYP2C9,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/805/original/hh-article03-08.pdf?1539206607,BE0002793
F3058,"CYP3A4 document, CTEP",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/058/original/cyp3a4.doc?1548197366,BE0002638
F3067,MEDICATIONS METABOLIZED BY CYTOCHROME P450 3A4,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/067/original/Methadone-Medications-Cytochrome-P450-3A4.pdf?1548263322,BE0002638
F3109,Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/109/original/f8f0fa4c75a43c495dc78c565e099be799dd.pdf?1548350296,BE0002638
F3112,Genetic Polymorphism of CYP2D6,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/112/original/Genetic_polymorphism_of_CYP2D6.pdf?1548350917,BE0002363
F1907,A Review on Drug Interactions in Oral Hypoglycemic Drugs by Mechanism of Cytochrome P450 Enzyme Inhibition,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/907/original/116434-271285-1-PB.pdf?1539880022,BE0002793
F1598,Ropinrole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/598/original/Ropinrole_FDA_label.pdf?1537463837,BE0002433
F1591,Theophylline FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/591/original/CYP1A2_Theophylline.pdf?1537457669,BE0002433
F3799,CYTOMEL (liothyronine) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/799/original/fda.pdf?1551828936,BE0003541
F1599,CTEP CYP1A2 DOCUMENT,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/599/original/cyp1a2.doc?1537465701,BE0002433
F1600,Ropivacaine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/600/original/Ropivacaine_FDA_label.pdf?1537466348,BE0002433
F3433,Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/433/original/10.1.1.572.1434.pdf?1549647650,BE0009626
F1983,Med-Psych Interactions Review: Triptans,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/983/original/Med-Psych_Interactions_Update-_Triptans.pdf?1540498480,BE0002198
F4139,Acetaminophen FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/139/original/Acetaminophen_Injection_FDA_label.pdf?1553717049,BE0003533
F3664,Codeine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/664/original/Codeine_FDA_label.pdf?1551127714,BE0002363
F3673,Codeine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/673/original/Codeine_FDA_label.pdf?1551131264,BE0002638
F3667,Codeine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/667/original/Codeine_FDA_label.pdf?1551129872,BE0003679
F3670,Codeine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/670/original/Codeine_FDA_label.pdf?1551130183,BE0003681
F2206,Dihydroergotamine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/206/original/Dihydroergotamine_FDA.pdf?1544554777,BE0002638
F3556,Amitriptyline FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/556/original/Amitriptyline_FDA_label.pdf?1550616396,BE0002363
F1466,Wang et al. (2004). Clin Pharmacol Ther. 75:191-197,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/466/original/CYP2C19__Wang_et_al..pdf?1536681026,BE0003536
F4685,FDA Label - Methadone,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/685/original/FDA_Label_-_methadone.pdf?1566927671,BE0002638
F4685,FDA Label - Methadone,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/685/original/FDA_Label_-_methadone.pdf?1566927671,BE0003536
F4685,FDA Label - Methadone,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/685/original/FDA_Label_-_methadone.pdf?1566927671,BE0002887
F4685,FDA Label - Methadone,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/685/original/FDA_Label_-_methadone.pdf?1566927671,BE0002433
F4685,FDA Label - Methadone,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/685/original/FDA_Label_-_methadone.pdf?1566927671,BE0002793
F1601,Olanzapine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/601/original/Olanzapine_FDA_label.pdf?1537471035,BE0002433
F1486,Olanzapine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/486/original/Olanzapine_FDA_label.pdf?1536947153,BE0003536
F1601,Olanzapine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/601/original/Olanzapine_FDA_label.pdf?1537471035,BE0002793
F3715,Prilosec FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/715/original/Prilosec_FDA.pdf?1551291606,BE0002638
F3706,Prilosec FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/706/original/Prilosec_FDA.pdf?1551224562,BE0003536
F2270,WHO: PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/270/original/who_emp_qsm2008.3.pdf?1544726582,BE0002638
F1295,Canadian DPD Label - LONITEN (minoxidil),//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/295/original/Canadian_DPD_Label_-_LONITEN_%28minoxidil%29.PDF?1535381202,BE0003541
F1514,Cancer. gov CTEP protocol developments,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/514/original/cyp2c19.doc?1537221138,BE0003536
F1906,A Review on Drug Interactions in Oral Hypoglycemic Drugs by Mechanism of Cytochrome P450 Enzyme Inhibition,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/906/original/116434-271285-1-PB.pdf?1539879975,BE0002793
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0002638
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0002363
F1602,Mirtazapine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/602/original/FDA_label__Mirtazapine.pdf?1537473633,BE0002433
F1627,Palonosetron FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/627/original/Palonosetron_FDA_label.pdf?1537568523,BE0002433
F3766,Amlodipine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/766/original/Amlodipine_FDA_label.pdf?1551718622,BE0002638
F4081,Carisoprodol FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/081/original/Carisoprodol_FDA_label.pdf?1553272900,BE0003536
F3931,Prometrium FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/931/original/Prometrium_FDA_label.pdf?1552429629,BE0002638
F1871,Sorafenib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/871/original/sorafenib_fda.pdf?1539705871,BE0002793
F1889,Rosiglitazone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/889/original/Rosiglitazone_fda.pdf?1539711844,BE0002793
F1525,Phenobarbital product monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/525/original/Phenobarbital_Product_Monograph.pdf?1537290567,BE0003536
F3862,Ambien FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/862/original/Ambien_FDA_label.pdf?1552002346,BE0002638
F4045,BMJ Article: Allopurinol metabolism in a patient with xanthine oxidase deficiency,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/045/original/Allopurinolmetabolismina_patientwithxanthine_oxidasedeficiency.pdf?1553117756,BE0003539
F3982,"FDA label, Allopurinol",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/982/original/Allopurinol_FDA_label.pdf?1552949475,BE0002204
F2219,Trimethoprim FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/219/original/Trimethoprim_FDA_label.pdf?1544568404,BE0002887
F762,Celestone monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/762/original/1.pdf?1532386869,BE0002638
F1904,Teniposide monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/904/original/Teniposide_monograph_1July2014.pdf?1539879288,BE0002793
F1632,FDA label Quinine,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198,BE0002433
F1899,Quinine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/899/original/FDA_label_Quinine.pdf?1539806359,BE0002793
F1928,Montelukast FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/928/original/FDA_label_montelukast.pdf?1539963705,BE0002793
F1603,Duloxetine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/603/original/Duloxetine_FDA_label.pdf?1537474340,BE0002433
F1626,Chlorpromazine Prescribing Info,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/626/original/Chlorpromazine-Thorazine-FDA-Label.pdf?1537563847,BE0002433
F1638,Nabilone FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/638/original/018677s011lbl.pdf?1537810630,BE0003533
F1922,Cimetidine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/922/original/Cimetidine_FDA_label.pdf?1539894834,BE0002793
F1816,Ritonavir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/816/original/RItonavir_FDA.pdf?1539294174,BE0002793
F1699,"FDA, ritonavir",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/699/original/Ritonavir_FDA.pdf?1538153612,BE0002433
F1644,Albendazole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/644/original/FDA_label_Albenza.pdf?1537820247,BE0002433
F1653,Erlotinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/653/original/Erlotinib_FDA.pdf?1537898295,BE0002433
F1829,Cyclophosphamide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/829/original/Cyclophosphamide_FDA.pdf?1539382562,BE0002793
F1875,Zafirlukast FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/875/original/zafi.pdf?1539707489,BE0002793
F1815,Bosentan FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/815/original/BOSENTAN_FDA_LABEL.pdf?1539292391,BE0002793
F1584,CP450 drug interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/584/original/cyp450_drug_interactions.pdf?1537394923,BE0002433
F1810,Tegretol FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/810/original/Tegretol_FDA.pdf?1539209452,BE0002793
F1614,Propranolol FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/614/original/propranolol_fda_label.pdf?1537552115,BE0002433
F2249,Inderal Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/249/original/Inderal_0.pdf?1544649987,BE0002198
F1924,"FDA label, Dilantin",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/924/original/Dilantin_Infatabs_OS_PM_E_19Dec2017.pdf?1539902326,BE0002793
F3964,FDA label Valacyclovir,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/964/original/FDA_label__Valacyclovir.pdf?1552928699,BE0002351
F3979,FDA label Valacyclovir,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/979/original/FDA_label__Valacyclovir.pdf?1552937954,BE0000514
F3949,"Valtrex tablets, MedSafe NZ",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/949/original/Valtrex_MedSafe_NZ.pdf?1552685757,BE0000514
F1876,Valdexocib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/876/original/FDA_label_Valdecoxib.pdf?1539707791,BE0002793
F1929,EMA public statement: Valdecoxib,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/929/original/emea-public-statement-valdecoxib-parecoxib-sodium-cardiovascular-risks-coronary-artery-bypass-graft_en.pdf?1539965585,BE0002793
F2210,Voriconazole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/210/original/Voriconazole_FDA_label.pdf?1544560320,BE0002638
F1869,Voriconazole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/869/original/Voriconazole_FDA_label.pdf?1539705288,BE0002793
F1698,Pharmacogenomic Association Table,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/698/original/Pharmacogenomic_Associations_Tables.pdf?1538151452,BE0002433
F1452,Pharmacists' Letter/Prescribers' Letter: Cytochrome P450 Drug Interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/452/original/cyp450_drug_interactions.pdf?1536601307,BE0002887
F1631,Imatinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/631/original/Imatinib_FDA_label.pdf?1537804473,BE0002433
F1898,Imatinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/898/original/Imatinib_FDA_label.pdf?1539805701,BE0002793
F1908,Efavirenz FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/908/original/Efavirenz_fda.pdf?1539881058,BE0002793
F1354,Efavirenz FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/354/original/Efavirenz_FDA_label.pdf?1535736090,BE0002638
F1711,Efavirenz FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/711/original/FDA_label_Efavirenz.pdf?1538412865,BE0002433
F1640,CYP1A2 cancer.gov document,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/640/original/cyp1a2.doc?1537816612,BE0002433
F1518,Cytochrome P450 drug interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/518/original/cyp450_drug_interactions.pdf?1537284698,BE0003536
F1519,Mayo medical laboratory document,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/519/original/Mayo_medical_laboratory_document.pdf?1537284852,BE0003536
F4655,FDA Label - Simvastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/655/original/FDA_Label_-_simvastatin.pdf?1564075804,BE0002638
F4658,Health Canada Monograph - Simvastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/658/original/Health_Canada_Monograph_-_Simvastatin.PDF?1564075821,BE0002638
F1964,Med-Psych Drug-Drug Interactions Update: Triptans,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/964/original/e267fbbcd72c2554dc36db979bad6935e7ee.pdf?1540417164,BE0002198
F1806,Aprepitant FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/806/original/Aprepitant_FDA_label.pdf?1539207345,BE0002793
F1931,Tamoxifen FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/931/original/Tamoxifen_FDA.pdf?1539966188,BE0002793
F1878,FDA label Losartan,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/878/original/FDA_label_losa.pdf?1539708399,BE0002793
F1879,Warfarin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/879/original/Warf_FDA.pdf?1539708508,BE0002793
F1592,FDA label warfarin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/592/original/FDA_label__Warfarin.pdf?1537459656,BE0002433
F787,Vienna presentation 2012,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/787/original/1.pdf?1532464324,BE0002638
F1616,Tizanidine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/616/original/tizanidine_fda_label.pdf?1537557887,BE0002433
F2273,Eplenerone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/273/original/Eplenerone_FDA_label.pdf?1544731885,BE0002638
F1863,Delavirdine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/863/original/Delarvidine_FDA_label.pdf?1539641661,BE0002793
F2009,Sufentanil EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/009/original/zalviso-epar-product-information_en.pdf?1541442012,BE0002638
F1932,Flurbiprofen FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/932/original/Flurbiprofen_FDA.pdf?1539966813,BE0002793
F1933,Nateglinide FD label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/933/original/Nateglinide_FDA.pdf?1539967335,BE0002793
F1617,Riluzole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/617/original/riluzole_fda_label.pdf?1537558079,BE0002433
F1934,Zileuton FDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/934/original/Zileuton_fda.pdf?1539967408,BE0002793
F1618,Zileuton FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/618/original/Zileuton_FDA.pdf?1537558677,BE0002433
F1439,Modafinil FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/439/original/Modafinil_FDA_label.pdf?1536356517,BE0003536
F1697,Pharmacogenomics Table,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/697/original/Pharmacogenomic_Associations_Tables.pdf?1538151397,BE0002433
F1833,Modafinil FDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/833/original/Modafinil_FDA_label.pdf?1539620768,BE0002793
F1834,Modafinil EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/834/original/modafinil-annex-iii-summary-product-characteristics-labeling-package-leaflet_en.pdf?1539621606,BE0002793
F1835,Modafinil FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/835/original/Modafinil_FDA_label.pdf?1539621622,BE0002793
F1700,"Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc)",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/700/original/cyp2b6.doc?1538154736,BE0003549
F1912,Clopidogrel FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/912/original/Clopidogrel_FDA_label.pdf?1539882625,BE0002793
F1681,Clopidogrel FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/681/original/Clopidogrel_fDA.pdf?1537991461,BE0002433
F1700,"Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc)",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/700/original/cyp2b6.doc?1538154736,BE0003549
F1649,"Malathion, Monograph",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/649/original/mono112-07.pdf?1537830005,BE0002433
F1880,Mefenamic Acid FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/880/original/Mefenamic_ACID_FDA.pdf?1539708891,BE0002793
F1811,"MONOGRAPH, Primidone",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/811/original/mono108-07.pdf?1539210539,BE0002793
F1462,"Primidine Prescribing Information, Canada",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/462/original/Primidione_Prescribing_Information__Canada.pdf?1536615314,BE0003536
F1512,Primidone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/512/original/Prescribing_information__primidone.pdf?1537218769,BE0003536
F1897,Atacand Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/897/original/ATACAND_-_Product-Monograph_001.pdf?1539799124,BE0002793
F1882,Meloxicam FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/882/original/Meloxicam_FDA_label.pdf?1539709436,BE0002793
F2200,Tadalafil FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/200/original/Tadalafil.pdf?1544547993,BE0002638
F1642,Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/642/original/fulltext_ajpt-v4-id1085.pdf?1537817645,BE0002433
F1538,Mifepristone FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/538/original/202107Orig1s000Lbl.pdf?1537305458,BE0002887
F1619,Dacarbazine monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/619/original/Dacarbazine_monograph_1June2013_formatted.pdf?1537560136,BE0002433
F2201,Vardenafil FDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/201/original/Vardenafil.pdf?1544548213,BE0002638
F1620,Zofran FDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/620/original/Zofran_FDA_label.pdf?1537560512,BE0002433
F1985,Med-Psych Review: Triptans,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/985/original/Med-Psych_Interactions_Update-_Triptans.pdf?1540498593,BE0002198
F1586,Cyclobenzaprine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/586/original/Cyclobenzaprine_FDA.pdf?1537396249,BE0002433
F1650,Maprotiline Data Sheet,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/650/original/Maprotiline_New_Zealand_Data_sheet.pdf?1537889787,BE0002433
F1984,Med-Psych Review: Triptans,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/984/original/Med-Psych_Interactions_Update-_Triptans.pdf?1540498548,BE0002198
F1963,Med-Psych Drug-Drug Interactions Update: Triptans,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/963/original/e267fbbcd72c2554dc36db979bad6935e7ee.pdf?1540417068,BE0002198
F1487,CTEP.gov CYP2C19 document,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/487/original/cyp2c19.doc?1536956758,BE0003536
F1488,"EMA label, Telmisartan",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/488/original/EMA_label__telmisartan.pdf?1536956852,BE0003536
F2102,DRUG-DRUG INTERACTIONS – FROM KNOWLEDGE BASE TO CLINICAL IMPACT,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/102/original/Thesis_Marine_Andersson.pdf?1543427453,BE0003677
F1593,Alosteron FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/593/original/FDA_label__Alosteron.pdf?1537460723,BE0002433
F1594,"CTEP CYP1A2 document, NIH",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/594/original/cyp1a2.pdf?1537461161,BE0002433
F1612,List of drugs that may have potential CYP2E1 interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/612/original/cyp2e1.doc?1537551487,BE0003533
F4694,Ezetimibe FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/694/original/Ezetimibe_FDA_label.pdf?1568145048,BE0002887
F1621,Ramelteon FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/621/original/Ramelton_FDA_label.pdf?1537561082,BE0002433
F1700,"Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc)",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/700/original/cyp2b6.doc?1538154736,BE0003549
F1622,Fovatriptan FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/622/original/Fova.pdf?1537561737,BE0002433
F1925,EMA Withdrawal Assessment Report for Direction (Ketoprofen Gel),//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/925/original/withdrawal-assessment-report-diractin_en.pdf?1539902762,BE0002793
F1623,Cinacalcet FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/623/original/Cinacalcet_FDA_label.pdf?1537562294,BE0002433
F763,Olux monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/763/original/1.pdf?1532387445,BE0002638
F1887,Irbesartan FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/887/original/Irbesartan_FDA_label.pdf?1539710687,BE0002793
F1651,"CYP1A2 document, cancer.gov",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/651/original/cyp1a2.doc?1537894349,BE0002433
F1888,"FDA label, Ibuprofen",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/888/original/Ibuprofen_FDA_label.pdf?1539710857,BE0002793
F1700,"Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc)",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/700/original/cyp2b6.doc?1538154736,BE0003549
F1930,Connecticut's Official State Website: CYP Chart,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/930/original/CYPChartNov2013pdf.pdf?1539966142,BE0002793
F1827,Fluvastatin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/827/original/Fluvastatin_fda.pdf?1539373889,BE0002793
F1909,Leflunomide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/909/original/Leflunomide_FDA_label.pdf?1539881381,BE0002793
F4652,Health Canada Monograph - Rosuvastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/652/original/Health_Canada_Label_-_Rosuvastatin.PDF?1563989610,BE0002793
F1590,Pimozide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/590/original/Pimozide_FDA.pdf?1537456704,BE0002433
F1861,Capecitabine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/861/original/Capecitabine_fDA_label.pdf?1539638974,BE0002793
F1700,"Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc)",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/700/original/cyp2b6.doc?1538154736,BE0003549
F2518,Bicalutamide Labeling,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/518/original/Bicalutamide_Labeling.pdf?1546879119,BE0002638
F1936,Carvedilol FDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/936/original/Carvedilol_FDA_label.pdf?1539969426,BE0002793
F1643,"FDA label, Carvedilol",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/643/original/Carvedilol_FDA.pdf?1537818564,BE0002433
F1589,Doxepin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/589/original/Doxepin_FDA_label.pdf?1537397432,BE0002433
F1700,"Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc)",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/700/original/cyp2b6.doc?1538154736,BE0003549
F1654,Cilostazol EMA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/654/original/Cilostazol_EMA.pdf?1537902988,BE0002433
F1807,Phenobarbital Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/807/original/Phenobarbital_Product_Monograph.pdf?1539207623,BE0002793
F1921,Auspar Cyclizine,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/921/original/auspar-cyclizine-lactate-130115.pdf?1539892503,BE0002793
F2830,Propafenone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/830/original/Propafenone_FDA_label.pdf?1547224520,BE0002363
F2830,Propafenone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/830/original/Propafenone_FDA_label.pdf?1547224520,BE0002638
F1624,Propafenone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/624/original/propafenone_fda_label.pdf?1537562720,BE0002433
F1647,Domperidone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/647/original/Domperidone_FDA_label.pdf?1537825060,BE0002433
F1812,Rifapentine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/812/original/RIfapentin.pdf?1539211801,BE0002793
F1813,Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/813/original/303.full.pdf?1539276370,BE0002793
F1433,Rifaximin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/433/original/Rifamixin_FDA.pdf?1536342184,BE0003536
F1580,"CYP1A2, CTEP document, NIH",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/580/original/cyp1a2.pdf?1537393556,BE0002433
F1581,Cytochrome P450 Drug Interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/581/original/cyp450_drug_interactions.pdf?1537393785,BE0002433
F922,FDA Label - ONIVYDE™ (irinotecan liposome injection),//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/922/original/FDA_Label_-_ONIVYDE%E2%84%A2_%28irinotecan_liposome_injection%29.pdf?1533073850,BE0003541
F2104,DRUG-DRUG INTERACTIONS – FROM KNOWLEDGE BASE TO CLINICAL IMPACT,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/104/original/Thesis_Marine_Andersson.pdf?1543428000,BE0003677
F2105,The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/105/original/a42abacc5d2af67bda8e706439f2fb7f1dad.pdf?1543428384,BE0003677
F1582,Cytochrome P450 Interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/582/original/cyp450_drug_interactions.pdf?1537393944,BE0003536
F1583,Clomipramine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/583/original/FDA_Clomipramine.pdf?1537394120,BE0003536
F1585,Clomipramine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/585/original/FDA_Clomipramine.pdf?1537395638,BE0002433
F2274,"FDA label, Ergonovine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/274/original/Methylgonorvine_FDA_label.pdf?1544732464,BE0002638
F2265,Dasatinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/265/original/sprycel-epar-product-information_en.pdf?1544724679,BE0002638
F2364,Vyvanse FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/364/original/Vyvanse_FDA_label.pdf?1545165585,BE0002363
F132,"EMA label, Lapatinib",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/132/original/EMA_label.pdf?1528400667,BE0002887
F770,Verdeso monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/770/original/1.pdf?1532451429,BE0002638
F1800,Formoterol FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/800/original/022007s004lbl.pdf?1539197397,BE0003336
F1890,Formoterol FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/890/original/022007s004lbl-2.pdf?1539713510,BE0002793
F1625,Rasagiline FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/625/original/Rasagiline_FDA_label.pdf?1537562987,BE0002433
F1803,Ciprofloxacin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/803/original/Ciprofloxacin_FDA.pdf?1539203883,BE0002433
F1577,Acenocoumarol monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/577/original/Sintrom_en.pdf?1537391347,BE0002433
F1577,Acenocoumarol monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/577/original/Sintrom_en.pdf?1537391347,BE0003536
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1524,Phenobarbital Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/524/original/Phenobarbital_Product_Monograph.pdf?1537290461,BE0003536
F1735,Quazepam FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/735/original/018708s018lbl.pdf?1538499862,BE0003549
F2271,Everolimus FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/271/original/Everolimus_FDA_label.pdf?1544727368,BE0002638
F1515,"Kaletra, FDA label",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/515/original/FDA_label__Kaletra.pdf?1537221939,BE0003536
F1820,Kaletra FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/820/original/FDA_label__Kaletra.pdf?1539298381,BE0002793
F1821,Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418,BE0002793
F1822,Kaletra EPAR,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/822/original/kaletra-epar-product-information_en.pdf?1539360078,BE0002793
F1750,Deferasirox FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/750/original/CYP1A2_Desferasirox.pdf?1538670223,BE0002433
F1752,Exjade EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/752/original/Exjade_EMA.pdf?1538670841,BE0002433
F1641,CYP1A2 cancer.gov document,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/641/original/cyp1a2.doc?1537816928,BE0002433
F1913,Etoricoxib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/913/original/Etoricoxib_EMA.pdf?1539883309,BE0002793
F1926,EMA Etoricoxib Assessment,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/926/original/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_en.pdf?1539903083,BE0002793
F1705,Etoricoxib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/705/original/Etoricoxib_FDA.pdf?1538174535,BE0002433
F1018,CYP1A2 interactions,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/018/original/fulltext_ajpt-v4-id1085.pdf?1533748543,BE0002433
F1706,"Review of Toxicological Literature, NIH",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/706/original/resveratrol_508.pdf?1538174757,BE0002433
F1637,"CYP1A2 document, cancer.gov",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/637/original/cyp1a2.doc?1537810601,BE0002433
F1836,CYP2C19 and CYP2C9: New aspects of pharmacogenetics and transcriptional regulation,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/836/original/b72f5f1e3db65e69d80fcff27b764fa6c84e.pdf?1539623371,BE0002793
F1910,Nilotinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/910/original/Nilotinib_FDA.pdf?1539881570,BE0002793
F973,Priligy Data Sheet,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/973/original/Priligytab.pdf?1533315053,BE0002363
F1893,Ximelagatran FDA Review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/893/original/84280017D2DC4084B88D22698665EABA.pdf?1539715748,BE0002793
F1873,Oritavancin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/873/original/Oritavancin_FDA.pdf?1539706705,BE0002793
F1490,Clevidipine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/490/original/Australian_Public_Assessment_Report-_Clevidipine.pdf?1536959804,BE0003536
F1676,Lofexidine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/676/original/Lofexidine_FDA_label.pdf?1537980976,BE0002433
F1680,Pirfenidone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/680/original/Pirfenidone_FDA_label.pdf?1537982169,BE0002433
F1496,Dexlanzoprazole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/496/original/Dexlanzoprazole_FDA.pdf?1536962749,BE0003536
F2309,Camptosar FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/309/original/Camptosar_FDA_label.pdf?1544829108,BE0002638
F2113,Telaprevir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/113/original/Telaprevir_FDA_label.pdf?1543443951,BE0002638
F1860,Brivaracetam FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/860/original/205836Orig1s000_205837Orig1s000_205838Orig1s000lbl.pdf?1539637180,BE0002793
F1754,Abiraterone FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/754/original/Abiraterone_FDA_label.pdf?1538673769,BE0002433
F1443,Zytiga product monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/443/original/Product_Monograph__Zytiga.pdf?1536358627,BE0003536
F1693,DOVITINIB LACTATE Multikinase Inhibitor Antiongiogenic Agent Oncolytic,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/693/original/%28PDF%29_DOVITINIB_LACTATE_Multikinase_Inhibitor_Antiongiogenic_Agent_Oncolytic.pdf?1538147508,BE0002433
F1713,Romidepsin FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/713/original/022393lbl.pdf?1538414579,BE0003549
F1885,Tapentadol FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/885/original/022304s003lbl.pdf?1539710283,BE0002793
F1884,Prasugrel FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/884/original/022307s002lbl.pdf?1539709914,BE0002793
F1656,Eltrombopag FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/656/original/Eltrombopag_FDA_label.pdf?1537903211,BE0002433
F1634,Asenapine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/634/original/Asenapine_FDA_label.pdf?1537809314,BE0002433
F1911,Sitaxentan Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/911/original/Monograph__Sitaxentan.pdf?1539881907,BE0002793
F1927,NPS Medicinewise Australian Prescriber: New Drugs,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/927/original/00804f708bf77b69e26e2f1ed7399ca081d894c713eb7752e303509af391.pdf?1539962927,BE0002793
F1483,"EMA Discussion Document, Sitaxentan",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/483/original/EMA_document_sitaxentan.pdf?1536870702,BE0003536
F2527,Simeprevir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/527/original/Simepravir_FDA_label.pdf?1546881223,BE0002638
F1724,Forxiga Assessment report,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/724/original/forxiga-epar-public-assessment-report_en.pdf?1538434127,BE0002433
F1905,Etravirine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/905/original/etravirine_fda.pdf?1539879709,BE0002793
F1510,"Selected Properties of Etravirine, HIVCLINIC.ca",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/510/original/NNRTI_etravirine.pdf?1537213291,BE0003536
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1657,"FDA Label, Pazopanib",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/657/original/Pazopanib_FDA.pdf?1537905265,BE0002433
F1695,Midostaurin fDA,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/695/original/Midostaurin_FDA.pdf?1538148509,BE0002433
F1746,Midostaurin FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/746/original/rydapt-epar-product-information_en.pdf?1538589714,BE0003549
F1507,Midostaurin EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/507/original/WC500237581.pdf?1537209776,BE0002887
F1851,Midostaurin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/851/original/Midostaurin_FDA_label.pdf?1539632401,BE0002793
F1852,Midostaurin EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/852/original/rydapt-epar-public-assessment-report_en.pdf?1539632437,BE0002793
F1495,"Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism and Excretion Studies of a BDDCS II Drug",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/495/original/Midostaurin.pdf?1536962250,BE0003536
F2196,Apixaban FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/196/original/Apixaban_FDA_label.pdf?1544547159,BE0002638
F1658,Apixaban FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/658/original/Apixaban_FDA_label.pdf?1537907015,BE0002433
F1659,Axitinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/659/original/Axitinib_FDA_label.pdf?1537907725,BE0002433
F1500,Safinamide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/500/original/Safinamide_FDA_label.pdf?1536966040,BE0003536
F1504,"Safinamide, Pharmacology Review, FDA",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/504/original/207145Orig1s000PharmR.pdf?1537198222,BE0003536
F4393,Dexmethylphenidate XR FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/393/original/Dexmethylphenidate_XR_Label.pdf?1555362204,BE0004387
F1856,Fosaprepitant FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/856/original/Fosaprepitant_FDA_label.pdf?1539634492,BE0002793
F1662,Bendamustine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/662/original/Bendamustine_FDA.pdf?1537908965,BE0002433
F1915,A Review on Drug Interactions in Oral Hypoglycemic Drugs by Mechanism of Cytochrome P450 Enzyme Inhibition,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/915/original/116434-271285-1-PB.pdf?1539884234,BE0002793
F1886,Vismodegib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/886/original/203388lbl.pdf?1539710613,BE0002793
F1492,Vismodegib,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/492/original/FDA_label__vismodegib.pdf?1536960870,BE0003536
F4667,FDA Label - Pitavastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/667/original/FDA_Label_-_Pitavastatin.pdf?1564609735,BE0003679
F4667,FDA Label - Pitavastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/667/original/FDA_Label_-_Pitavastatin.pdf?1564609735,BE0003677
F1883,Pitavastatin FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/883/original/022363s000_Lbl.pdf?1539709679,BE0002793
F4667,FDA Label - Pitavastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/667/original/FDA_Label_-_Pitavastatin.pdf?1564609735,BE0002887
F2182,Rilpivirine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/182/original/Rilpivirine_FDA_label.pdf?1544472714,BE0002638
F1526,Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/526/original/anticonvulsant-int.pdf?1537291056,BE0003536
F2328,Ulipristal FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/328/original/FDA_label_ulipristal.pdf?1545079372,BE0002638
F2114,Boceprevir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/114/original/Boceprevir_FDA_label.pdf?1543446183,BE0002638
F1881,Cabozantinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/881/original/208692s000lbl.pdf?1539709355,BE0002793
F1702,"FDA label, Teriflunomide",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/702/original/Teriflunomide_FDA_label.pdf?1538155367,BE0002433
F1540,Vemurafenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/540/original/202429s012lbl-3.pdf?1537307489,BE0002887
F1782,Vemurafenib EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/782/original/anx_133338_en.pdf?1538779315,BE0003549
F1682,Perampanel FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/682/original/Perampanel_FDA.pdf?1537995594,BE0002433
F400,Regorafenib,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/400/original/regorafenib.pdf?1530737152,BE0002638
F400,Regorafenib,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/400/original/regorafenib.pdf?1530737152,BE0003538
F1732,Regorafenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/732/original/203085lbl.pdf?1538498947,BE0003549
F400,Regorafenib,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/400/original/regorafenib.pdf?1530737152,BE0003541
F1837,Enzalutamide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/837/original/Enzalutamide_FDA_label.pdf?1539623762,BE0002793
F1838,Xtandi Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/838/original/Xtandi_PM_EN.pdf?1539624088,BE0002793
F1520,Ezalutamide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/520/original/Ezalutamide_FDA_label.pdf?1537286678,BE0003536
F1733,Enzalutamide FDA Review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/733/original/203415Orig1s000ClinPharmR.pdf?1538499376,BE0003549
F1513,Xtandi monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/513/original/1.pdf?1537219227,BE0002362
F4316,"FDA label, Invokana",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/316/original/Invokana_FDA_label.pdf?1554933115,BE0003538
F4313,"Invokana, Canadian monograph",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/313/original/Invokana__Canadian_monograph.pdf?1554913610,BE0003538
F4316,"FDA label, Invokana",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/316/original/Invokana_FDA_label.pdf?1554933115,BE0003681
F4313,"Invokana, Canadian monograph",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/313/original/Invokana__Canadian_monograph.pdf?1554913610,BE0003681
F4316,"FDA label, Invokana",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/316/original/Invokana_FDA_label.pdf?1554933115,BE0002638
F1660,Pomalidomide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/660/original/FDA_label__pomalidomide.pdf?1537908060,BE0002433
F527,EMA Label: Tafinlar (dabrafenib mesilate) Summary of Product Characteristics,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/527/original/WC500149671.pdf?1531326533,BE0002793
F1441,Luliconazole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/441/original/Luliconazole_FDA_label.pdf?1536357038,BE0003536
F1801,Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/801/original/Determination_of_the_inhibitory_potential_of_6_fluoroquinolones_on_CYP1A2_and_CYP2C9_in_human_liver_.pdf?1539203695,BE0002433
F1802,"FDA label, ciprofloxacin",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/802/original/Ciprofloxacin_FDA.pdf?1539203799,BE0002433
F1877,Netupitant FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/877/original/205718s000lbl.pdf?1539708002,BE0002793
F1493,Australian Public Assessment Report: Naloxegol,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/493/original/auspar-naloxegol-oxalate-160601.pdf?1536961409,BE0003536
F1491,Lumacraftor Australian Prescribing Information,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/491/original/auspar-lumacaftor-ivacaftor-160908-pi.pdf?1536959860,BE0002887
F1744,Idelalisib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/744/original/205858lbl.pdf?1538589070,BE0003549
F1857,Cannabidiol World Health Organization Review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/857/original/5.2_CBD.pdf?1539635882,BE0002793
F1677,Tasimelteon FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/677/original/Tasimelteon_FDA_label.pdf?1537981173,BE0002433
F2974,Linparza (olaparib) drug monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/974/original/olaparib_%28capsule%29.pdf?1547681847,BE0002638
F1742,Olaparib Health Canada Product Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/742/original/00045123.PDF?1538588569,BE0003549
F1743,Olaparib EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/743/original/lynparza-epar-product-information_en.pdf?1538588669,BE0003549
F1874,Olodaterol FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/874/original/203108s006lbl.pdf?1539707193,BE0002793
F773,Nerisone monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/773/original/1.pdf?1532452451,BE0002638
F2266,FDA label: Stribild,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/266/original/Elvitegravir_FDA.pdf?1544725244,BE0002638
F1388,"EMA label, stiripentol",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/388/original/Stiripentol_and_EMA_label.pdf?1536161386,BE0003536
F1388,"EMA label, stiripentol",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/388/original/Stiripentol_and_EMA_label.pdf?1536161386,BE0002433
F1444,Zuacta Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/444/original/zuacta_monograph.pdf?1536359200,BE0003536
F1868,Zuacta Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/868/original/Zuacta_Monograph.pdf?1539642694,BE0002793
F1639,"Sanofi Canada: ZUACTA (zucapsaicin cream, 0.075% w/w) Prescribing Information",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/639/original/zuacta.pdf?1537810886,BE0003533
F2289,WHO Critical Review: Etizolam,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/289/original/WHO_Crit.pdf?1544745221,BE0003536
F1675,Zotepine monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/675/original/zotepine_monograph.pdf?1537980859,BE0002433
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1830,Artesunate and Amiodiquine FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/830/original/Artesunate_and_Amodiquine.pdf?1539617705,BE0003336
F1745,Lumacaftor/Ivacaftor FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/745/original/uspi_lumacaftor_ivacaftor-2.pdf?1538589421,BE0003549
F1506,Lumacaftor/Ivacaftor FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/506/original/uspi_lumacaftor_ivacaftor.pdf?1537209167,BE0002887
F1839,Lumacaftor FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/839/original/Lumacaftor_FDA_label.pdf?1539624333,BE0002793
F1521,Lumacaftor FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/521/original/Lumacaftor_FDA_label.pdf?1537288298,BE0003536
F1685,Propacetamol Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/685/original/PROPACETAMOL_PRESCRIBING_INFO.pdf?1538001584,BE0002433
F1701,Osimertinib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/701/original/Osimertinib_FDA.pdf?1538154826,BE0002433
F1608,List of Drugs Interacting with CYP3A4 - The Cancer Therapy Evaluation Program (CTEP),//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/608/original/List_of_Drugs_Interacting_with_CYP3A4_-_The_Cancer_Therapy_Evaluation_Program_%28CTEP%29.pdf?1537544013,BE0002638
F1661,Ixazomib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/661/original/Ixazomib.pdf?1537908566,BE0002433
F1712,Ixazomib EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/712/original/ninlaro-epar-product-information_en.pdf?1538414359,BE0003549
F1474,EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/474/original/WC500217620.pdf?1536793163,BE0002887
F1865,Ixazomib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/865/original/208462lbl.pdf?1539642476,BE0002793
F1723,A Review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L),//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/723/original/peppermint_oil.pdf?1538429254,BE0002433
F1475,Selexipag FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/475/original/207947s001lbl.pdf?1536793316,BE0002887
F804,"Melegestrol acetate, Australia",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/804/original/1.pdf?1532544308,BE0002638
F1862,Lesinurad FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/862/original/207988lbl.pdf?1539641643,BE0002793
F2123,Venclexta FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/123/original/Venclexta_FDA_label.pdf?1543868185,BE0002638
F1714,Sofosbuvir and Velpatasvir FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/714/original/208341s007lbl.pdf?1538414793,BE0003549
F1715,Sofosbuvir and Velpatasvir EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/715/original/epclusa-epar-product-information_en.pdf?1538414830,BE0003549
F1477,"VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) FDA Label",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/477/original/vosevi_pi.pdf?1536861147,BE0002887
F1859,Rupatadine Canadian Prescribing Information,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/859/original/RUPALL-monograph-EN.pdf?1539636355,BE0002793
F1505,Opicapone EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/505/original/Opicapone_EMA.pdf?1537199944,BE0003536
F1497,Opicapone EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/497/original/anx_135047_en.pdf?1536965128,BE0002887
F1854,Isavuconazole FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/854/original/Isavuconazole_FDA_label.pdf?1539633382,BE0002793
F1696,Pitilosant FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/696/original/Pitilosant_FDA.pdf?1538148649,BE0002433
F1748,Pitolisant EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/748/original/anx_133706_en.pdf?1538592778,BE0003549
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0002793
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0002638
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0003549
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0002433
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0002363
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0002281
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0000807
F114,"European Medicines Agency (EMA): Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/114/original/WC500144564.pdf?1527261710,BE0000814
F379,Encorafenib review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/379/original/Encorafenib_Review.pdf?1530720666,BE0002638
F379,Encorafenib review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/379/original/Encorafenib_Review.pdf?1530720666,BE0003536
F379,Encorafenib review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/379/original/Encorafenib_Review.pdf?1530720666,BE0002363
F763,Olux monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/763/original/1.pdf?1532387445,BE0002638
F1776,Biktarvy FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/776/original/BIktarvy_fda.pdf?1538773116,BE0003657
F3814,Spravato FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/814/original/Spravato_FDA_label.pdf?1551896525,BE0003549
F3817,Spravato FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/817/original/Spravato_FDA_label.pdf?1551896554,BE0002638
F3820,Spravato FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/820/original/Spravato_FDA_label.pdf?1551897479,BE0003536
F3823,Spravato FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/823/original/Spravato_FDA_label.pdf?1551897504,BE0002793
F4108,Brexanolone FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/108/original/211371lbl.pdf?1553536038,BE0000747
F1481,Apalutamide FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/481/original/210951s000lbl-2.pdf?1536864092,BE0002887
F1431,Apalutamide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/431/original/Apalutamide_FDA.pdf?1536340059,BE0003536
F1432,Erleada (apalutamide) monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/432/original/Erleada_FDA_label.pdf?1536340075,BE0003536
F1819,Apalutamide FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/819/original/Apalutamide_FDA.pdf?1539297404,BE0002793
F1823,Erleada monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/823/original/ERLEADA-pi.pdf?1539361821,BE0002793
F365,FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/365/original/Binetinib_FDA.pdf?1530652661,BE0003541
F366,EMA assessment report,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/366/original/EMA_withdrawal_letter.pdf?1530652749,BE0003541
F367,EMA assessment report,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/367/original/EMA_withdrawal_letter.pdf?1530652842,BE0002433
F1725,"FDA label, Binimetinib",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/725/original/FDA_label_bini.pdf?1538434262,BE0002433
F1824,Avatrombopag FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/824/original/Avatrombopag_FDA_label.pdf?1539362386,BE0002793
F1665,Voxilaprevir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/665/original/Voxilaprevir_FDA.pdf?1537911858,BE0002433
F1666,Management of Unique Populations with HCV Infection,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/666/original/a2c6786846e0cb95193716302d2cc4b6b757.pdf?1537912099,BE0002433
F1478,"VOSEVI ( (sofosbuvir, velpatasvir, and voxilaprevir) FDA Label",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/478/original/vosevi_pi.pdf?1536861615,BE0002887
F1522,Letermovir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/522/original/LETERMOVIR_FDA_LABEL.pdf?1537288530,BE0003536
F1523,Letermovir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/523/original/Prevymis__EMA_label.pdf?1537288966,BE0003536
F1853,Letermovir FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/853/original/letermovir_fda.pdf?1539632684,BE0002793
F1747,Letermovir EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/747/original/prevymis-epar-public-assessment-report_en.pdf?1538591893,BE0003549
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0002793
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0002638
F1664,Deutetrabenazine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/664/original/Deutetrabenazine_FDA.pdf?1537911236,BE0002433
F3571,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/571/original/Egaten_FDA_label.pdf?1550684579,BE0002433
F3568,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/568/original/Egaten_FDA_label.pdf?1550684563,BE0002793
F3577,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/577/original/Egaten_FDA_label.pdf?1550685318,BE0002638
F3580,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/580/original/Egaten_FDA_label.pdf?1550685347,BE0003543
F3583,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/583/original/Egaten_FDA_label.pdf?1550685388,BE0001111
F3586,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/586/original/Egaten_FDA_label.pdf?1550685417,BE0003536
F3589,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/589/original/Egaten_FDA_label.pdf?1550685445,BE0002363
F3592,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/592/original/Egaten_FDA_label.pdf?1550686032,BE0003336
F3595,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/595/original/Egaten_FDA_label.pdf?1550686050,BE0002887
F3598,Egaten FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/598/original/Egaten_FDA_label.pdf?1550686065,BE0003549
F1473,Eravacycline FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/473/original/Eravacycline_FDA_label.pdf?1536790055,BE0002638
F1473,Eravacycline FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/473/original/Eravacycline_FDA_label.pdf?1536790055,BE0002198
F1663,Rupacarib,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/663/original/Rupacarib_FDA.pdf?1537909073,BE0002433
F4196,Siponimod FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/196/original/Siponimod_FDA_label.pdf?1554153879,BE0002638
F4196,Siponimod FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/196/original/Siponimod_FDA_label.pdf?1554153879,BE0002793
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F767,Eumovate cream monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/767/original/1.pdf?1532446750,BE0002638
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1454,Acid peptic diseases: pharmacological approach to treatment,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/454/original/Acid_peptic_diseases_Pharmacological_approach_to_t.pdf?1536602544,BE0003536
F1668,Enasidenib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/668/original/Enadisenib_FDA_label.pdf?1537912686,BE0002433
F1716,Enasidenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/716/original/209606s000lbl-2.pdf?1538416178,BE0003549
F1479,Enasidenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/479/original/209606s000lbl.pdf?1536861874,BE0002887
F1858,Enasidenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/858/original/209606s000lbl-3.pdf?1539636102,BE0002793
F1498,Enasidenib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/498/original/Enasidenib_FDA.pdf?1536965261,BE0003536
F119,Amino Acid Sequence of Phospholipase AZ-a! from the Venom of Crotalus adamanteus,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/119/original/J._Biol._Chem.-1977-Heinrikson-4913-21.pdf?1527281760,BE0000070
F1499,Eurartesim EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/499/original/piperaquine.pdf?1536965668,BE0003536
F1670,CYP1A2 CTEP cancer.gov,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/670/original/cyp1a2.doc?1537975412,BE0002433
F1669,"CYP1A2 document, cancer.gov",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/669/original/cyp1a2.doc?1537914124,BE0002433
F1671,CYP1A2 CTEP cancer.gov,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/671/original/cyp1a2.doc?1537975784,BE0002433
F1673,Cancer.gov CTEP CYP1A2 document,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/673/original/cyp1a2.doc?1537979489,BE0002433
F1674,CYP1A2 cancer.gov CTEP,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/674/original/cyp1a2.doc?1537980001,BE0002433
F2079,Baloxavir Marboxil FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/079/original/Baloxavir_Marboxil_FDA_label.pdf?1543256133,BE0003677
F2079,Baloxavir Marboxil FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/079/original/Baloxavir_Marboxil_FDA_label.pdf?1543256133,BE0002638
F1840,Nabilone FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/840/original/018677s011lbl-2.pdf?1539624376,BE0002793
F1842,Nabiximols AUSPAR Profile,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/842/original/auspar-nabiximols-130927-pi.pdf?1539625514,BE0002793
F1686,"CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/686/original/Europe_CYP1A2.pdf?1538062575,BE0002433
F1683,"Pilocarpine pharmacology review, FDA",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/683/original/200890_pilocarpine_clinpharm_PREA.pdf?1537998135,BE0002433
F1749,Ivosidenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/749/original/211192s000lbl-2.pdf?1538592989,BE0003549
F1855,Ivosidenib FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/855/original/Ivosidenib_FDA_label.pdf?1539634060,BE0002793
F1508,Ivosidenib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/508/original/211192s000lbl.pdf?1537211522,BE0002887
